In addition, SCH772984 plus apatinib has been effective against oral squamous cell carcinoma (OSCC) [45], and SCH772984 is also an alternative for the treatment of LKB1 and LKB1/KRAS-mutated NSCLC [46]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.